BackgroundObesity is associated with significant physical, psychosocial and economic burden globally. In Brazil, almost 50% of the population is either overweight or obese. The prevalence of morbid obesity increased by 255% between 1975 and 2003. The current study sought to quantify the relationship between weight status and health outcomes.MethodsData from three waves (2011, 2012, and 2015) of the Brazil National Health and Wellness Survey, an Internet-based survey administered to a demographically diverse sample of Brazilian adults, were used. Body mass index category was calculated based on self-reported height and weight and respondents were categorized into five groups (normal, overweight, obese class I, obese class II, obese class III; n = 34,254). Multivariable analyses, controlling for sociodemographic variables and health history, tested the association with body mass index group and outcomes including health status (Medical Outcomes Study Short Form 12-Item Health Survey version 2/Medical Outcomes Study Short Form 36-Item Health Survey version 2), work productivity (Work Productivity and Activity Impairment-General Health Questionnaire), and costs associated with work impairment (indirect costs), self-reported healthcare resource use and associated direct costs.ResultsOverall, 53.6% of the surveyed Brazilian population reported being overweight or obese. In virtually all the analyses, increasing body mass index group was associated with significant and progressively worse outcomes. Most notable was the finding that hospitalization costs were over twice as high (R$3141.84 vs. R$1349.60) and indirect costs were nearly double (R$1656.80 vs. R$884.15) for obesity class III than for normal body mass index respondents.ConclusionsObesity rates in Brazil are considerable and, from a patient and societal perspective, increasingly burdensome, thereby highlighting the need for stakeholders to prioritize strategies for weight management interventions.
Objectives: To estimate long-term clinical outcomes of using rilpivirine/tenofovir/emtricitabine (single tablet regimen) in treatment of naïve patients with HIV-1 RNA< 100 000 copies/ml in the Russian Federation. MethOds: The mathematical model was developed in Microsoft Office 2013. The time horizon was 5 years. The model included two submodels: Markov's model and tree-decision model. The following outcome measures were used in present study: Number of deaths, Years of life lost, Number of hospitalizations. All calculations were based on results of published clinical, epidemiological and social researches. Data for patients with HIV was obtained from prior epidemiological studies that had been provided in the Russian Federation. Results: The number of deaths on rilpivirine/tenofovir/emtricitabine scheme (single tablet regimen) was 12% and 15% less, the number of YLL was 9% and 12% less and Number of hospitalizations was 19,91% and 19,88% less than on the schemes efavirenz + tenofovir/ emtricitabin (multi-pill regimen) and lopinavir + tenofovir/ emtricitabin (multi-pill regimen), respectively. cOnclusiOns: Results obtained with present model showed that treatment naïve patients with HIV-1 RNA< 100 000 copies/ml using rilpivirine/tenofovir/emtricitabine scheme (single tablet regimen) can be associated with better long-term outcomes compared to alternative multi-pill schemes.
Objective: The aim of the current analysis was to measure the public health impact of dengue vaccination in Brazil using a published transmission dynamics model. Methods: We adapted a mathematical model that represented the transmission dynamics of the four dengue fever serotypes in humans and in the mosquito. This compartmental model represents the known characteristics of dengue transmission dynamics: host-vector interactions, immunological interactions between all four dengue serotypes, age structure of the population, levels of specific transmission by age, seasonality of the disease, and growth of the human and vector population. Results: Our mathematical model showed a 22% (CI95%: 9-37) reduction of all cases of dengue fever for a smaller scenario (routine vaccination at 9 years old and catch-up campaign to 10 years of age) and 81% (CI95%: 67-89) in the largest scenario (routine vaccination at 9 years old and catch-up campaign to 40 years of age) over a 5-year period. For the 10-year impact, we estimated a 22% (CI95%: 12-39) reduction in the smaller scenario, and a 92% (CI95%: 80-95) reduction in the larger scenario. This reduction in the number of cases would lead to significant decrease in the number of hospitalizations. Up to 233,509 (CI95%: 148,534-331,849) and 739,378 (CI95%: 604,386-894,072) hospitalizations would be prevented over a 5-year and 10-year period, respectively, with the larger vaccination program. Conclusion: This analysis indicates that, within expected variations, a national dengue vaccination program in Brazil would lead to significant public health benefits by reducing dengue infections and hospitalizations.
Objective: The aim of the current analysis was to measure the public health impact of dengue vaccination in Brazil using a published transmission dynamics model. Methods: We adapted a mathematical model that represented the transmission dynamics of the four dengue fever serotypes in humans and in the mosquito. This compartmental model represents the known characteristics of dengue transmission dynamics: host-vector interactions, immunological interactions between all four dengue serotypes, age structure of the population, levels of specific transmission by age, seasonality of the disease, and growth of the human and vector population. Results: Our mathematical model showed a 22% (CI95%: 9-37) reduction of all cases of dengue fever for a smaller scenario (routine vaccination at 9 years old and catch-up campaign to 10 years of age) and 81% (CI95%: 67-89) in the largest scenario (routine vaccination at 9 years old and catch-up campaign to 40 years of age) over a 5-year period. For the 10-year impact, we estimated a 22% (CI95%: 12-39) reduction in the smaller scenario, and a 92% (CI95%: 80-95) reduction in the larger scenario. This reduction in the number of cases would lead to significant decrease in the number of hospitalizations. Up to 233,509 (CI95%: 148,849) and 739,378 (CI95%: 604,072) hospitalizations would be prevented over a 5-year and 10-year period, respectively, with the larger vaccination program. Conclusion: This analysis indicates that, within expected variations, a national dengue vaccination program in Brazil would lead to significant public health benefits by reducing dengue infections and hospitalizations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.